Insider Buying: SciClone Pharmaceuticals Director Purchases 25,040 Shares of Stock (SCLN)
SciClone Pharmaceuticals (NASDAQ:SCLN) Director Nancy T. Chang purchased 25,040 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 15th. The shares were purchased at an average cost of $6.00 per share, with a total value of $150,240.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.96% on Tuesday, hitting $6.34. 409,581 shares of the company’s stock traded hands. SciClone Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $6.43. The stock has a 50-day moving average of $5.21 and a 200-day moving average of $4.90. The company has a market cap of $323.8 million and a P/E ratio of 14.95.
SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.10. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $33.40 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Analysts expect that SciClone Pharmaceuticals will post $0.49 EPS for the current fiscal year.
SciClone Pharmaceuticals, Inc (NASDAQ:SCLN) is a specialty pharmaceutical company.
Receive News & Ratings for SciClone Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.